SOLIGENIX, INC. Amortization of Debt Issuance Costs and Discounts
SOLIGENIX, INC. (SNGX) reported Amortization of Debt Issuance Costs and Discounts of $12.52 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2025-03-21
- SOLIGENIX, INC. amortization of debt issuance costs and discounts for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- SOLIGENIX, INC. amortization of debt issuance costs and discounts for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- SOLIGENIX, INC. amortization of debt issuance costs and discounts for the quarter ending 2023-06-30 was $2.28K, a 78.02% decline year-over-year.
- SOLIGENIX, INC. amortization of debt issuance costs and discounts for the quarter ending 2023-03-31 was $10.24K, a 0.00% change year-over-year.
- SOLIGENIX, INC. amortization of debt issuance costs and discounts for fiscal 2023 was $12.52K, a 69.86% decline from fiscal 2022.
- SOLIGENIX, INC. amortization of debt issuance costs and discounts for fiscal 2022 was $41.54K, a 0.93% decline from fiscal 2021.
- SOLIGENIX, INC. amortization of debt issuance costs and discounts for fiscal 2021 was $41.93K.
- SOLIGENIX, INC. amortization of debt issuance costs and discounts for fiscal 2015 was $10.65K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $0.00 derived: sum of 2 quarters · filed 2025-03-21 | $2.28K derived: sum of 3 quarters · filed 2025-03-21 | $12.52K 10-K · filed 2025-03-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $2.28K derived: sum of 2 quarters · filed 2024-11-08 | $12.52K 10-Q · filed 2024-11-08 | $22.99K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $2.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $12.52K 10-Q · filed 2024-08-09 | $22.99K derived: sum of 3 quarters · filed 2024-08-09 | $33.46K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $10.24K 10-Q · filed 2024-05-10 | $20.71K derived: sum of 2 quarters · filed 2024-05-10 | $31.18K derived: sum of 3 quarters · filed 2024-05-10 | $41.54K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $10.47K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $20.94K derived: sum of 2 quarters · filed 2024-03-15 | $31.30K derived: sum of 3 quarters · filed 2024-03-15 | $41.54K 10-K · filed 2024-03-15 |
| 2022-09-30 | $10.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $20.83K derived: sum of 2 quarters · filed 2023-11-13 | $31.07K 10-Q · filed 2023-11-13 | $41.54K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $10.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $20.60K 10-Q · filed 2023-08-21 | $31.07K derived: sum of 3 quarters · filed 2023-08-21 | $41.54K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $10.24K 10-Q · filed 2023-05-15 | $20.71K derived: sum of 2 quarters · filed 2023-05-15 | $31.18K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $10.47K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $20.94K derived: sum of 2 quarters · filed 2023-03-31 | $41.93K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $10.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $31.46K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $20.99K 10-Q · filed 2022-08-12 | |||
| 2016-03-31 | $6.25K 10-Q · filed 2016-05-12 | $12.57K derived: sum of 2 quarters · filed 2016-05-12 | ||
| 2015-12-31 | $6.32K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-24 | $10.65K 10-K · filed 2016-03-24 | ||
| 2015-09-30 | $4.33K 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |